Pfizer to buy cancer drugmaker Seagen in $43 billion deal
Pfizer will pay $229 a share in cash for Seagen, according a statement Monday, about a third more than the drugmaker’s closing share price Friday.
Pfizer will pay $229 a share in cash for Seagen, according a statement Monday, about a third more than the drugmaker’s closing share price Friday.